Last reviewed · How we verify
Chlorpromazine Pill
Chlorpromazine acts as a dopamine antagonist, blocking dopamine receptors in the brain.
Chlorpromazine acts as a dopamine antagonist, blocking dopamine receptors in the brain. Used for Schizophrenia, Acute psychosis.
At a glance
| Generic name | Chlorpromazine Pill |
|---|---|
| Also known as | Temozolomide |
| Sponsor | Marco G Paggi, MD, PhD |
| Drug class | Phenothiazine antipsychotic |
| Target | Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
This leads to a decrease in the activity of the dopaminergic system, which is involved in the regulation of movement and other functions. Chlorpromazine's mechanism of action is complex and multifaceted, involving the blockade of multiple dopamine receptor subtypes. This results in a range of therapeutic effects, including the reduction of psychotic symptoms and the management of movement disorders.
Approved indications
- Schizophrenia
- Acute psychosis
Common side effects
- Drowsiness
- Dizziness
- Dry mouth
- Weight gain
- Parkinsonian symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorpromazine Pill CI brief — competitive landscape report
- Chlorpromazine Pill updates RSS · CI watch RSS
- Marco G Paggi, MD, PhD portfolio CI